Skip to content
Search

Latest Stories

Former NPA director Phil Galt named new Cegedim Rx UK managing director

Former NPA director Phil Galt named new Cegedim Rx UK managing director

Phill Galt replaces Adam Dennett who stepped down from the Cegedim Rx's leadership role after a successful ten-year tenure 

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx.


The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said.

Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5).

Tristan de Foucher, head of European operations for Cegedim Group, said: “Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy.”

Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

More recently, Galt simultaneously served as the managing director and superintendent pharmacist for Lindsay & Gilmour Pharmacy, an independent chain comprising 32 locations.

Previously, he held positions as a non-executive director on the board of the National Pharmacy Association Insurance Company (NPAI) and as a director of the Association of Independent Multiple Pharmacies (AIMp).

Galt also served as a trustee for the NPA Health Education Foundation, a charity set up to advance public education in the prevention and proper treatment of disease by encouraging greater research within community pharmacy.

Commenting on his appointment, Phil said: “I know the pressures of delivering frontline care in community pharmacy and just how challenging it can be to juggle this alongside managing a sustainable and profitable business.

“I’m therefore truly looking forward to bringing Cegedim Rx my 20 years of customer experience and industry expertise in order to accelerate the company’s product innovation and revenue growth.”

Foucher expressed his delight in having someone of Galt's caliber and industry experience join the company

“Phil Galt is an industry visionary with a proven track record of execution.

“It is an exciting moment in the life of Cegedim Rx and we welcome his leadership to federate the team behind his expertise, enable enhanced support to pharmacists and deliver better patient outcomes,”  he said.

Cegedim Rx offers a comprehensive suite of pharmacy software solutions, including PMR system Pharmacy Manager, Pharmacy Services and Pharmacy Intelligence Hub.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less